Anne Dam Jensen is a prominent inventor based in Copenhagen, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of interferon gamma polypeptide variants. With a total of eight patents to her name, her work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Among her latest patents, one notable invention is the development of novel full-length interferon gamma (IFNG) polypeptide variants. These variants exhibit interferon gamma activity and are obtained through specific modifications in the C-terminal part of the molecule. They are particularly useful in therapy for interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. Another significant patent involves polynucleotides encoding interferon gamma polypeptides. This invention describes a conjugate that exhibits interferon gamma activity, comprising a non-polypeptide moiety covalently linked to an IFG polypeptide. This conjugate may be utilized for the treatment of various diseases.

Career Highlights

Anne has worked with notable companies in the biotechnology sector, including Maxygen Holdings Ltd. and Maxygen Aps. Her experience in these organizations has contributed to her expertise in the field and her ability to innovate effectively.

Collaborations

Throughout her career, Anne has collaborated with esteemed colleagues such as Kim Vilbour Andersen and Christian Hansen. These partnerships have likely enhanced her research and development efforts.

Conclusion

Anne Dam Jensen is a distinguished inventor whose work in interferon gamma polypeptide variants holds promise for advancing therapeutic options in medicine. Her contributions to biotechnology continue to pave the way for innovative treatments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com